logo


Generex to Raise $12.25 Million in Registered Direct Offering
Tuesday, September 15, 2009 10:55 AM


(Source: Datamonitor)trackingGenerex Biotechnology, a developer of drug delivery systems and technologies, has received commitments from investors to purchase $12.25 million of securities in a registered direct offering.

Generex expects to receive net proceeds of approximately $11.66 after deducting placement agent fees and other offering expenses.

Generex has entered into securities purchase agreements with the investors pursuant to which Generex has agreed to sell an aggregate of 15.31 million shares of its common stock and warrants to purchase up to 5.05 million additional shares of its common stock. Each unit, consisting of one share of common stock and a warrant to purchase one-third of a share of common stock, will be sold for a purchase price of $0.80.

The warrants to purchase additional shares will be exercisable at an exercise price of $1 per share beginning 183 days after issuance and will expire five years from the date they are first exercisable.

Proceeds from the transaction will be used for general corporate purposes. The offering is expected to be consummated by September 14, 2009, subject to customary closing conditions. Midtown Partners & Co and Maxim Group acted as co-placement agents for the transaction.

A service of YellowBrix, Inc.



(0)
No Comments
Post Comment
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
   
 
 
 
 
   
 

  
Related Press Releases
Advertisement
Popular Articles
Advertisement
Partner Center
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia